NEW YORK, April 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders announced today its Chief Executive Officer Mr. Robb Knie will be joined by other members of the management team to ring the NASDAQ Closing Bell on Monday, April 22, 2019 to celebrate the Company's recent listing to the NASDAQ Capital Market. 

"Ringing the NASDAQ closing bell following our initial public offering to the exchange in February of this year, highlights what an exciting time it is at the company," stated Mr. Robb Knie, CEO of Hoth Therapeutics. "As we celebrate this milestone, I wanted to extend my deepest thanks and appreciation to our team, advisors, Board members and shareholders who have supported us in our mission of making a difference in the lives of patients confronting these conditions.  Management is proud to be listed on the renowned NASDAQ exchange and we look forward to communicating our many successes to our investors in the future."

The Hoth Therapeutics closing bell ceremony will be aired live on April 22, 2019 at 4:00 PM (Eastern Time) at https://livestream.com/nasdaq/live and on the NASDAQ MarketSite Tower at 43rd and Broadway in New York, NY.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contact

Investor Relations Contact:
Phone: (646) 756-2997
Email: [email protected]  
www.hoththerapeutics.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-to-ring-nasdaq-closing-bell-on-april-22-2019-300834392.html

SOURCE Hoth Therapeutics, Inc.